U. Ploug

Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus.

S. Heller, A. Lloyd, A. Barnett, 2011, Clinical therapeutics.

Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care

M. Evans, M. Nyeland, L. García Álvarez, 2015, International journal of clinical practice.

The Cost of Diabetes-Related Complications: Registry-Based Analysis of Days Absent from Work

J. Sørensen, U. Ploug, 2013 .

Impact of obesity and type 2 diabetes on health-related quality of life in the general population in England

S. Gough, N. Kragh, M. Hammer, 2009, Diabetes, metabolic syndrome and obesity : targets and therapy.

Investigating the Evidence of the Real-Life Impact of Acute Hyperglycaemia

S. Heller, N. Kragh, A. Nikolajsen, 2015, Diabetes Therapy.

Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis

J. Jansen, M. Lorenzi, M. Zoratti, 2016, Diabetes Therapy.

Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden

M. Dorkhan, P. Matsson, G. Johansson, 2016, Diabetes Therapy.

Characteristics of newly diagnosed adults with type 1 diabetes in the UK and evolution of glycaemic control, body mass index and Charlson comorbidity index over the first 5 years after diagnosis.

N. Kragh, S. Ramtoola, M. Nyeland, 2020, Primary care diabetes.